Company news

Orion Oyj news in 2026

Orion Oyj's news releases, calls and decks from 2026, newest first.

View company

Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026

October 14, 2026

Orion Corporation: Acquisition of own shares during week 40, 2026

September 30, 2026

Orion Corporation: Acquisition of own shares during week 37, 2026

September 11, 2026

Orion Corporation: Acquisition of own shares during week 36, 2026

September 4, 2026

Orion Group Half-Year Financial Report January–June 2026

July 17, 2026

Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026

July 3, 2026

Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission

June 23, 2026

105,950 Orion Corporation A shares converted into B shares

May 15, 2026

Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs

May 12, 2026

Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours

April 23, 2026

Orion Corporation: Managers’ transactions – Satu Ahomäki

March 10, 2026

Orion Corporation: Managers’ transactions – René Lindell

March 10, 2026

Orion Corporation: Managers’ transactions – Outi Vaarala

March 10, 2026

Orion Corporation: Managers’ transactions – Niclas Lindstedt

March 10, 2026

Orion Corporation: Managers’ transactions – Mikko Kemppainen

March 10, 2026

Orion Corporation: Managers’ transactions – Liisa Hurme

March 10, 2026

Orion Corporation: Managers’ transactions – Julia Macharey

March 10, 2026

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

March 10, 2026

Orion Corporation: Managers’ transactions – Hao Pan

March 10, 2026

Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026

March 10, 2026

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

March 6, 2026

Orion Group Financial Statement documents 2025 and Remuneration Report published

February 27, 2026

The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons

February 12, 2026

Notice to the Annual General Meeting of Orion Corporation

February 12, 2026

Orion Group Financial Statement Release January–December 2025

February 12, 2026

62,752 Orion Corporation A shares converted into B shares

February 3, 2026

Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026

January 30, 2026

182,827 Orion Corporation A shares converted into B shares

January 16, 2026

Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting

January 15, 2026

Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion

January 14, 2026

Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future

January 14, 2026

Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)

January 8, 2026

Calls in 2026

Decks in 2026